276236-96-5

Basic information

• Product Name: 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine hydrochloride
• Synonyms: 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine hydrochloride;piperidine, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)-;4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine(SALTDATA: HCl);4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine HCl
• CAS NO: 276236-96-5
• Molecular Formula: C₁₃H₁₅N₃O
• Molecular Weight: 265.73864
• Mol File: 276236-96-5.mol

Chemical Properties

• Boiling Point: 391.9°C at 760 mmHg
• Flash Point: 190.8°C
• Appearance: /
• Density: 1.139g/cm³
• Vapor Pressure: 2.39E-06mmHg at 25°C
• Refractive Index: 1.548
• PKA: 9.57±0.10(Predicted)
• CAS DataBase Reference: 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine hydrochloride(276236-96-5)
• EPA Substance Registry System: 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine hydrochloride(276236-96-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 276236-96-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H15N3O/c1-2-4-10(5-3-1)12-15-13(17-16-12)11-6-8-14-9-7-11/h1-5,11,14H,6-9H2

Upstream product

• 126501-70-0 1-(2,2,2-trifluoroacetyl)piperidine-4-carboxylic acid 
• 280110-59-0 2,2,2-trifluoro-1-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethanone 
• 498-94-2 isonipecotic acid 
• 100-47-0 benzonitrile 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 276236-86-3 tert-butyl 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate 
• 613-92-3 N-hydroxybenzenecarboximidamide 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 613-92-3 N-hydroxyl-benzamidine 

Relevant articles and documents

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119

A series of xanthine compounds derived from the previous hit 20i with modification on the terminal side chain was discovered through ring formation strategy. Systematic optimization of the compounds with rigid heterocycles in the hydrophobic side chain led to the new lead compound HBK001 (21h) with the improved DPP-IV inhibition and moderate GPR119 agonism activity in vitro. As a continuing work to further study the PK and PD profiles, 21h and its hydrochloride (22) were synthesized on grams scale and evaluated on the ADME/T and oral glucose tolerance test (OGTT) in ICR mice. Compound 22 showed the improved bioavailability and blood glucose-lowering effect in vivo compared to its free base 21h probably attributed to its improved solubility and permeability. The preliminary toxicity studies on compound 22 exhibited that the result of mini-Ames was negative and the preliminary acute toxicity LD50 in mice was above 1.5 g/kg, while it showed moderate inhibition on hERG channel with IC50 4.9 μM maybe due to its high lipophilicity. These findings will be useful for the future drug design for more potent and safer dual ligand targeting DPP-IV and GPR119 for the treatment of diabetes.

Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists

Recent findings have shown that Farnesoid X Receptor (FXR) antagonists might be useful in the treatment of cholestasis and related metabolic disorders. In this paper, we report the discovery of a new chemotype of FXR antagonists featured by a 3,5-disubsti

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

COMPOUNDS HAVING AN ETHR INHIBITING ACTIVITY - USE OF SAID COMPOUNDS AS DRUGS - PHARMACEUTICAL COMPOSITION AND PRODUCT CONTAINING SAID COMPOUNDS

The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals : (II); (III); (IV), (V), (VI) (VII) and n= 1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.